These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22012607)

  • 1. [Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma].
    Kluge R; Körholz D
    Klin Padiatr; 2011 Nov; 223(6):315-9. PubMed ID: 22012607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma.
    Paulino AC; Margolin J; Dreyer Z; Teh BS; Chiang S
    Pediatr Blood Cancer; 2012 Jun; 58(6):860-4. PubMed ID: 21826784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
    Molin D; Hagberg H; Suurküla M; Aström G
    Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
    [No Abstract]   [Full Text] [Related]  

  • 4. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
    Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
    J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Georgi TW; Kluge R; Kurch L; Chavdarova L; Hasenclever D; Stoevesandt D; Pelz T; Landman-Parker J; Wallace WH; Karlen J; Fernández-Teijeiro A; Cepelova M; Fosså A; Balwierz W; Attarbaschi A; Ammann RA; Pears J; Hraskova A; Uyttebroeck A; Beishuizen A; Dieckmann K; Leblanc T; Daw S; Baumann J; Körholz D; Sabri O; Mauz-Körholz C
    J Nucl Med; 2018 Oct; 59(10):1524-1530. PubMed ID: 29653979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemoradiotherapy in early Hodgkin lymphoma.
    André MP
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):33-47. PubMed ID: 24287066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma.
    Rogasch JMM; Hundsdoerfer P; Hofheinz F; Wedel F; Schatka I; Amthauer H; Furth C
    BMC Cancer; 2018 May; 18(1):521. PubMed ID: 29724189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma.
    Marzolini M; Wong WL; Ardeshna K; Padhani A; D'Sa S
    Br J Haematol; 2012 Mar; 156(5):557. PubMed ID: 22150023
    [No Abstract]   [Full Text] [Related]  

  • 11. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
    Biggi A; Gallamini A; Chauvie S; Hutchings M; Kostakoglu L; Gregianin M; Meignan M; Malkowski B; Hofman MS; Barrington SF
    J Nucl Med; 2013 May; 54(5):683-90. PubMed ID: 23516309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
    Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol.
    Körholz D; Kluge R; Wickmann L; Hirsch W; Lüders H; Lotz I; Dannenberg C; Hasenclever D; Dörffel W; Sabri O
    Onkologie; 2003 Oct; 26(5):489-93. PubMed ID: 14605468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma.
    Agrawal K; Mittal BR; Bansal D; Varma N; Srinivasan R; Trehan A; Manohar K; Kashyap R; Bhattacharya A; Marwaha RK
    Ann Nucl Med; 2013 Feb; 27(2):146-51. PubMed ID: 23143537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FDG-PET in Hodgkin lymphoma].
    Kobe C; Dietlein M; Mauz-Körholz C; Engert A; Borchmann P; Sabri O; Schober O; Schicha H; Kluge R
    Nuklearmedizin; 2008; 47(6):235-8; quiz N75-6. PubMed ID: 19057796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients-Importance of multimodality imaging: Results from the EuroNet-PHL-C1 trial.
    Kurch L; Mauz-Körholz C; Fosså A; Georgi TW; Kluge R; Bartelt JM; Kunze C; Wohlgemuth WA; Pelz T; Vordermark D; Plößl S; Hasenclever D; Sabri O; Landman-Parker J; Wallace WH; Karlen J; Fernández-Teijeiro A; Cepelova M; Klekawka T; Løndalen AM; Steiner D; Krombach G; Attarbaschi A; Hoffmann M; Ceppi F; Pears J; Hraskova A; Uyttebroeck A; Beishuizen A; Dieckmann K; Leblanc T; Daw S; Körholz D; Stoevesandt D
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28903. PubMed ID: 33538093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moskowitz CH; Zelenetz A; Schoder H
    J Natl Compr Canc Netw; 2010 Mar; 8(3):347-52. PubMed ID: 20202464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
    Evens AM; Kostakoglu L
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
    Adams HJ; Kwee TC
    Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.